Bhatt RS - Search Results

1

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS. Zhang L, et al. Among authors: bhatt rs. Clin Cancer Res. 2015 Apr 15;21(8):1925-1934. doi: 10.1158/1078-0432.CCR-14-2031. Epub 2015 Jan 14. Clin Cancer Res. 2015. PMID: 25589614 Free PMC article.

2

Biomarkers for monitoring antiangiogenic therapy.

Bhatt RS, Seth P, Sukhatme VP. Bhatt RS, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):777s-780s. doi: 10.1158/1078-0432.CCR-06-1922. Clin Cancer Res. 2007. PMID: 17255309 Review.

3

Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.

Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP. Gallagher DC, et al. Among authors: bhatt rs. Clin Cancer Res. 2007 Apr 1;13(7):2115-20. doi: 10.1158/1078-0432.CCR-06-2509. Clin Cancer Res. 2007. PMID: 17404094

4

The challenge of herbal therapies for prostate cancer.

Bhatt RS, Bubley GJ. Bhatt RS, et al. Clin Cancer Res. 2008 Dec 1;14(23):7581-2. doi: 10.1158/1078-0432.CCR-08-2316. Clin Cancer Res. 2008. PMID: 19047081 Review.

5

Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.

Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF. Cho DC, et al. J Immunother. 2009 Feb-Mar;32(2):181-5. doi: 10.1097/CJI.0b013e3181952b1d. J Immunother. 2009. PMID: 19238017

6

A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.

Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP. Bhatt RS, et al. Cancer. 2010 Apr 1;116(7):1751-6. doi: 10.1002/cncr.24902. Cancer. 2010. PMID: 20120033 Free PMC article. Clinical Trial.

7

Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.

Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW. Bhatt RS, et al. Mol Cancer Ther. 2010 Oct;9(10):2793-802. doi: 10.1158/1535-7163.MCT-10-0477. Epub 2010 Aug 10. Mol Cancer Ther. 2010. PMID: 20699227 Free PMC article.

8

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.

Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS. Zhang L, et al. Among authors: bhatt rs. PLoS One. 2011 Apr 29;6(4):e19144. doi: 10.1371/journal.pone.0019144. PLoS One. 2011. PMID: 21559452 Free PMC article.

9

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma.

Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV. Bhatt RS, et al. Br J Cancer. 2011 Jun 28;105(1):112-7. doi: 10.1038/bjc.2011.186. Epub 2011 Jun 14. Br J Cancer. 2011. PMID: 21673679 Free PMC article.

10

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.

Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS. Wang X, et al. Among authors: bhatt rs. J Transl Med. 2011 Dec 21;9:220. doi: 10.1186/1479-5876-9-220. J Transl Med. 2011. PMID: 22188900 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

160 results

Search Page

Filters